Dominic Jainy stands at the fascinating intersection of silicon and surgery. As an IT professional with deep roots in artificial intelligence, machine learning, and blockchain, he has spent years observing how these technologies migrate from laboratory whiteboards to the high-stakes environment of the modern hospital. His perspective is unique because he doesn’t just see the code; he sees the clinical impact and the economic engines driving the next generation of healthcare. Today, we sit down with Dominic to dissect the massive capital shifts and technological breakthroughs that are redefining what it means to invest in the future of medicine as we approach 2026.
Our conversation covers the surge of nearly $18 billion in capital into the healthcare AI sector, the operational success of dominant players in robotic surgery, and the high-risk, high-reward nature of precision medicine startups. We also explore the tactical advantages of using diversified ETFs to mitigate the inherent risks of a strictly regulated industry, providing a roadmap for balancing aggressive growth with long-term stability.
In 2025, we witnessed a staggering $18 billion flow into healthcare AI. Where exactly is this capital being deployed, and what does it tell us about the industry’s immediate priorities?
When you see $18 billion moving into a single niche, it’s a clear signal that the market is moving past theoretical hype and into functional implementation. The majority of these funds are being funneled into three critical pillars: clinical documentation, diagnostics, and drug discovery. The focus on documentation is particularly telling; it’s an attempt to use AI to strip away the administrative friction that burns out doctors, allowing them to focus on the patient. However, it’s not all smooth sailing, as the sector is navigating an incredibly strict regulatory system that can act as a double-edged sword. While these regulations ensure safety, they also mean that capital must be patient, as the journey from a laboratory breakthrough to a bedside application is often long and fraught with oversight.
Intuitive Surgical has long been the titan of robotic surgery. How do their recent financial performance and system installations suggest a shift in the way hospitals are adopting automated technology?
The numbers coming out of Intuitive Surgical are nothing short of a masterclass in scaling complex technology. In the first quarter of 2026, their revenue reached $2.77 billion, which is a significant 23% jump compared to the previous year, while their adjusted earnings per share rose to $2.50. What’s truly impressive isn’t just the revenue, but the sheer velocity of adoption; they installed 431 da Vinci systems across the globe in just three months. We are seeing a massive appetite for their Ion systems as well, with usage increasing by 39%, alongside a 17% rise in their core da Vinci and Ion systems combined. This tells me that hospitals are no longer just “testing” robotics; they are integrating these data-driven tools as the standard of care for minimally invasive procedures.
Tempus AI is often cited as a high-potential but risky play in precision medicine. What should investors understand about their focus on data integration, and what metrics are essential to track for such a growth-stage company?
Tempus AI is operating at the absolute cutting edge by leveraging AI to enable precision medicine, particularly in sensitive areas like oncology, cardiovascular disease, and radiology. Listed under the symbol TEM on the Nasdaq since 2024, they are trying to solve the puzzle of integrating genomic, clinical, and imaging information into a single, actionable insight for clinicians. Because they are still a growth-stage business, the risk profile is much higher than a legacy provider, making it essential for investors to keep a sharp eye on their cash burn and revenue growth. You really have to look at the adoption rates among hospitals and life sciences customers to see if the technology is actually sticking. If their margins don’t start to stabilize as they scale, the excitement around their genome sequencing capabilities won’t be enough to sustain the stock’s momentum.
GE HealthCare seems to offer a more grounded, less momentum-driven entry into this space. How does their acquisition strategy and current market pricing reflect their role in the AI ecosystem?
GE HealthCare is a fascinating case because it offers AI exposure through the lens of a massive, established infrastructure. They aren’t a pure-play AI startup, but their scale gives them a massive advantage in imaging and workflow automation, operating through four main segments: medical imaging, ultrasound, patient care, and pharmaceutical diagnostics. They’ve been very aggressive and smart with their acquisitions, picking up Caption Health in 2023 and a clinical AI business from Intelligent Ultrasound in 2024 to bolster their tech stack. Currently trading near $64, which is about 27.77% below its 52-week high of $89.77, the stock represents a much more conservative entry point. For an investor who wants to avoid the “AI bubble” volatility, GE HealthCare provides a way to play the trend without the stomach-churning price swings of more aggressive growth stocks.
Given the volatility and regulatory hurdles in this sector, how can diversified ETFs like BOTZ, ROBT, or ROBO help an investor capture the upside while managing the inherent risks of individual stocks?
The beauty of these ETFs is that they allow you to bet on the “house” rather than a single player. For instance, the Global X Robotics and Artificial Intelligence ETF, known as BOTZ, manages about $3.52 billion in assets and provides a concentrated look at robotics and automation with an expense ratio of 0.68%. If you want something broader, the First Trust Nasdaq AI and Robotics ETF, or ROBT, holds 114 different stocks and charges a slightly lower 0.65%, covering everything from cybersecurity to AI infrastructure alongside healthcare. Then there’s ROBO, which manages $2.05 billion and is unique because it doesn’t let a single large holding dominate the portfolio, ensuring that your exposure to genetic sequencing or robotic surgery is truly diversified. These funds act as a safety net; if one clinical trial fails or one company faces a regulatory setback, the broader growth of the automation and AI sectors keeps the portfolio buoyant.
What is your forecast for the healthcare AI sector as we look toward the end of this decade?
I believe we are entering an era where the “AI” label will eventually vanish because the technology will simply be an invisible, integrated part of every medical device and software platform. The current trend of massive capital inflows—like that $18 billion we discussed—will likely lead to a period of consolidation where the big players like GE HealthCare and Intuitive Surgical acquire the most successful innovators like Tempus AI. We will see the “da Vinci” systems of the world becoming even more autonomous, potentially handling certain routine parts of a procedure while the surgeon supervises. For the reader, my forecast is one of cautious optimism: the strict regulatory environment will keep the “junk” products out of the market, but it also means that only the companies with the strongest balance sheets and the most proven clinical outcomes will survive. Investors should look for a mix of established leaders and broad-based ETFs to capture this growth without overextending themselves on any single high-risk venture.